NCT01426763View on ClinicalTrials.gov

A Study to Evaluate the Safety and Pharmacology of Subcutaneous Administration of CINRYZE With Recombinant Human Hyaluronidase

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 12, 2011

Primary Completion Date

November 28, 2011

Study Completion Date

November 28, 2011

Conditions
Hereditary Angioedema
Interventions
BIOLOGICAL

CINRYZE with rHuPH20

Trial Locations (4)

30342

ViroPharma Investigational Site, Atlanta

75231

ViroPharma Investigational Site, Dallas

85251

ViroPharma Investigational Site, Scottsdale

94598

ViroPharma Investigational Site, Walnut Creek

Sponsors

Lead Sponsor

Shire

Collaborators (1)

Halozyme Therapeutics
All Listed Sponsors
collaborator

Halozyme Therapeutics

INDUSTRY

lead

Shire

INDUSTRY

NCT01426763 - A Study to Evaluate the Safety and Pharmacology of Subcutaneous Administration of CINRYZE With Recombinant Human Hyaluronidase | Biotech Hunter | Biotech Hunter